K2 HealthVentures Equity Trust LLC 13D and 13G filings for TScan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:33 pm Sale |
2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 3,602,700 6.900% |
-1,721,444 (-32.33%) |
Filing |
| 2024-11-14 4:05 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% |
736,110 (+16.04%) |
Filing |
| 2024-02-14 4:45 pm Purchase |
2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% |
2,488,225 (+118.50%) |
Filing |
| 2022-09-30 5:21 pm Purchase |
2022-09-09 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% |
2,099,809 (New Position) |
Filing |